Dublin, 24 March 2021 (GLOBE NEWSWIRE) – Added to the report “COVID-19 Vaccine Market – Global Forecast and Forecast 2021-2024” ResearchAndMarkets.com’s offering.
The global COVID-19 vaccine market with revenues of USD 5 billion is expected to reach 2021-2024.
The market size of COVID-19 vaccine is expected to reach more than 5 billion by 2024. A stable focus by government agencies and several vaccine manufacturers is expected to prevent human and economic losses caused by the COVID-19 virus. worldwide to stimulate market growth. .
With several vendors implementing new strategies, including phase 1 & 2 clinical trial standards and faster regulatory approval from health organizations, vaccine doses are likely to become available worldwide. during the expected period.
Global vaccine market seal COVID-19
The global Covid-19 vaccine market research report introduces a detailed breakdown by technology, geography. Protein-based vaccines are the top segment of the COVID-19 vaccine market because they contain the purified pieces of a pathogen rather than the entire pathogen to stimulate an immune response. In the absence of any significant adverse effects on the human body, these vaccines are likely to see significant growth in the forecast period.
Novavax, Chinese Academy, and GSK / Sanofi are the main manufacturers that have approved protein-based vaccines for emergency use approval. Protein-based vaccines can be used in patients with associated immune responses.
Views by Geography
The spread of the COVID-19 pandemic has been seen worldwide. Countries such as the UK, USA, Italy, Spain, India, China were the most influential; however, the countries of the Middle East and Africa saw a moderately low incidence rate. The APAC market topped the global COVID-19 vaccine market with over 58% share, followed by Europe with 15% and North America with 12%.
The Middle East and Africa, and Latin America accounted for 10% and 6%, respectively. Since the outbreak began in 2019, which was declared a pandemic by the WHO in March 2020, the spread has been thick and rapid, shifting country by country and region by region.
Vendor Views
AstraZeneca, GlaxoSmithKline, Moderna, Gamaleya, Bharat Biotech, and Pfizer are major manufacturers of COVID-19 vaccines. The biotechnology and pharmaceutical industries are highly competitive and are characterized by rapid and significant progress in vaccine development. Multiple products have been approved by the USFDA, EU, and other regulatory bodies for emergency use permit (EUA) worldwide. Many products are made using the latest vaccine platforms in the market.
Key questions answered
1. What manufacturers are coming up with COVID-19 vaccines in 2021?
2. What are the main challenges facing retailers in circulating the COVID-19 vaccine?
3. What is the market size of COVID-19 vaccine by 2021?
4. Who are the key players in the market?
5. Which sectors are likely to generate the most revenue in 2021?
The following factors appear to be contributing to the growth of the COVID-19 market in the forecast period:
- Increased campaigns for COVID-19 vaccines
- Next Generation Vaccine Platforms for COVID-19 vaccine
- Rapid regulatory agreements for COVID-19 vaccines
Famous sellers
- AstraZeneca
- GlaxoSmithKline
- Moderna
- Gamaleya
- Biratch Bharat
- Pfizer
- Johnson & Johnson
- BioNTech
- CureVac
- Serum Institute of India
- Novavax
- Sinovac
- Sinopharm
Upcoming vendors
- AnGes
- AIVITA Biomedicine
- CanSinoBio
- EuBiologics
- Genexine
- GreenLight Biology
- Gennova
- Heat biology
- INOVIO
- IIBR
- Medicago
- Symvivo
- Valneva
- Zydus Cadila
Key topics covered:
1 Research Methodology
2 Research Objectives
3 Research Process
4 Scope & Coverage
4.1 Market definition
4.2 Foundation Year
4.3 Scope of the Audit
5 Describe assumptions & caves
5.1 Main Caves
5.2 Conversion of Money
5.3 Market yield
6 Market eye
7 Introduction
7.1 Preview
8 Market Opportunities and Trends
8.1 Upcoming COVID-19 vaccines
8.2 COVID-19 vaccination campaigns
8.3 Emergence of Next Generation Vaccine Platforms
9 Enable Market Growth
9.1 Accelerated Regulatory Agreements of COVID-19 vaccines
9.2 Increase the number of COVID-19 patients
9.3 Contract Manufacturers Accelerate COVID-19 Vaccine Production
10 Market barriers
10.1 Circulation of COVID-19 vaccines among LMICs
10.2 Adverse events and negative effects of permitted vaccines
10.3 Low uptake of COVID-19 vaccine
11 Market landscape
11.1 Market outlook
11.2 COVID-19 vaccine pipeline
11.3 Market Size & Forecast
11.4 COVID-19 supply chain
11.5 The role of contract manufacturers in the manufacture of COVID-19 vaccines
11.6 Five Force Audit
12 Technology
12.1 Preview
12.2 Vector-based COVID-19 vaccine
12.3 COVID-19 vaccine based on nuclear acid
12.4 Protein-based COVID-19 vaccine
12.5 Full virus COVID-19 vaccine
13 Geography
13.1 Market Snapshot & Growth Engine
13.2 Geographical Prospects
For more information about this report, visit https://www.researchandmarkets.com/r/cbobxh